Oxford Biomedica (OXBDF) Upgraded by Zacks Investment Research to “Buy”

Oxford Biomedica (NASDAQ:OXBDF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, October 18th. The firm presently has a $0.25 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 92.31% from the company’s current price.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Oxford Biomedica (NASDAQ OXBDF) traded up $0.02 during trading on Wednesday, reaching $0.13. 214 shares of the company were exchanged.

ILLEGAL ACTIVITY WARNING: “Oxford Biomedica (OXBDF) Upgraded by Zacks Investment Research to “Buy”” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://baseballnewssource.com/markets/oxford-biomedica-oxbdf-raised-to-buy-at-zacks-investment-research/1723440.html.

About Oxford Biomedica

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Get a free copy of the Zacks research report on Oxford Biomedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.